Doripenem vs meropenem against Pseudomonas and Acinetobacter.
Loading...
Date
2012-07
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Recently, doripenem has been approved for the treatment of nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP). The E-test was performed to determine the MICs of doripenem and meropenem in 203 endotracheal aspirate isolates that consisted of 140 Acinetobacter calcoaceticus-Acinetobacter baumannii complexes and 63 Pseudomonas aeruginosa. Doripenem showed minimum concentration necessary for inhibition of 50% (MIC 50 ) of P. aeruginosa isolates at 0.38 mg/L which is several times (84.2 times) lower than the corresponding MIC 50 value of >32 mg/L for meropenem. The MIC 50 and MIC 90 were similar for both the drugs against A. baumannii. Thus, P. aeruginosa was consistently more susceptible than the A. baumannii.
Description
Keywords
Acinetobacter, doripenem, meropenem, MIC, Pseudomonas
Citation
Goyal K, Gautam V, Ray P. Doripenem vs meropenem against Pseudomonas and Acinetobacter. Indian Journal of Medical Microbiology. 2012 Jul-Sept; 30(3): 350-351.